In conclusion, our biomarker analyses suggest the requirement of tumor GPC3 and blood CD16 as the necessary biomarker to achieve codrituzumab efficacy under the context of adequate codrituzumab exposure. The gene discussed is GPC3; the disease is neoplasm.